Lv7
4280 积分 2026-04-23 加入
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma
1个月前
已完结
Exposure-Response Relationship of the Bruton Tyrosine Kinase Inhibitor, Zanubrutinib (BGB-3111) in Patients with Hematologic Malignancies
1个月前
已关闭
Pharmacokinetics‐Bridging Between Autoinjectors and Prefilled Syringes for Subcutaneous Injection: Case Examples Revealing a Knowledge Gap
1个月前
已完结
Release of silicone oil and the off-label use of syringes in ophthalmology
2个月前
已完结
Silicone oil droplets in repackaged anti–vascular endothelial growth factors for intravitreal injections: In search of the main source of contamination
2个月前
已完结
Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling
2个月前
已完结
Incidence of Presumed Silicone Oil Droplets in the Vitreous Cavity After Intravitreal Bevacizumab Injection With Insulin Syringes
2个月前
已完结
Antitumor Cytotoxic Activity Retained in Tolerized T Cells Following Daily Dose Escalation of a T‐Cell Engager in Cynomolgus Monkeys to Mitigate Cytokine Release Syndrome
2个月前
已完结
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib
2个月前
已完结
Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies
2个月前
已完结